Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
MELBOURNE - CSL (OTC:CSLLY) Limited (ASX:CSL) shares fell 5% after the global biotechnology company reported mixed results for the first half of fiscal year 2025, with its vaccine division Seqirus underperforming analysts’ forecasts. The company cited reduced immunization rates in the U.S. as a key factor impacting its performance.
CSL’s Seqirus vaccine unit saw revenue decline 9% YoY to $1.66 billion for the six months ended December 31, 2024, falling 15% short of analyst expectations. This weakness in the vaccine segment overshadowed the company’s overall financial results.
Net profit rose 6% to $2.01 billion, slightly below the $2.09 billion consensus estimate, driven by a 10% revenue increase in CSL’s main blood-plasma business, Behring.
CEO Paul McKenzie attributed the disappointing vaccine performance to post-COVID apathy among U.S. adults aged 18-64 and reduced vaccine access.
"Performance has been negatively impacted by the significant decline in immunisation rates in the U.S.," McKenzie stated on the earnings call. He added, "The incidence of influenza and hospitalisation rates are up and this poses a significant public health risk."
The company did not provide specific guidance for the upcoming quarters or fiscal year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.